Dennis McGrath: So, Anthony, first off and combine that with the question that Ross asked earlier. Since we have onboarded our first customer, we don’t have permission from New Jersey Cancer Care to reveal their client and patient as we onboard additional customers that will be blind in terms of the size of their practice, their expectation, the amount of patients we have on there. I will tell you, they’re very enthusiastic about the initial tranche of patients that have been onboarded. They have a fairly robust practice call it 100s of patients that are opportunities. These all represent revenue to the practice. So they’re aspirational as well. As we onboard the additional clients that are in the pipeline that will become clearer in terms of what the likely predictive amount of the patient population versus those that get on our platform.
As Lishan indicated, we model this at $80 per month per patient. It could be higher than that for a variety of reasons, but conservatively that’s what it represents. So if you have a practice with a 1,000 patients that are targeted at $80 a month, you’re talking about an $80,000 a month opportunity. And some of these practices are even larger than that that are in our pipeline. So it’s still early to kind of provide any guidelines or guideposts in terms of what that expectation is. We know the platform works. We know that customers are extremely pleased with it. The data that’s being reported is affecting patient care and we know that the reimbursement’s already in place and unlikely to change, so we don’t have that battle to fight. So there’s lots of reasons to be optimistic about what the prospects here are, but to draw a picture of exactly what that might be like throughout 2023 is a little bit challenging this early in the end game.
Lishan Aklog: I’ll add just one generic kind of qualitative comment to that, which is, it is interesting like, unlike other commercialization of other products where you may have up months, you may have down months and so forth. The mechanics here do argue for the likelihood of having sort of escalating numbers within a given practice because the way they generally approach it and again, I’m making this as a generic comment not for the specific practice that we launched is that you start with your highest risk patients and you get comfortable with 50 patients or 100 patients or so forth that you think would be most likely to benefit, and then expand it out to a greater and greater portion of the cancer patients within your practice.
And so because it’s recurring revenue, because of that dynamic of starting with a core group and expanding it out, we have reason to believe that this will reflect the business model as we’ve described it. That once you have a practice onboard that you €“ that we would see escalating numbers of patients at some trajectory being onboarded on the system, them staying on the system for their duration of care, which is typically a minimum of six months, usually a year, sometimes as long as two years. And so that’s kind of the dynamic we expect, which could very well €“ which we think will be different than sort of just a traditional medical device commercialization prospect where it’s just one €“ one-offs, volumes up, volumes down, overall trends and so forth.
So hopefully that that has a bit of color there .
Anthony Vendetti: No. That was great, Lishan. Yes, that’s the trajectory I thought, but I just wanted to make sure that made sense.
Lishan Aklog: Yes. That’s the dynamic.
Anthony Vendetti: Yes. Perfect. And you have some large practices in the pipeline in addition to the one you’re working with?
